Editor's Pick: The week ahead....
(AVCT.L) Avacta Group PLC Buy/Sell
1.88
+0.00
(0%)
Add to portfolio
Set Alert
Level 2
Desktop Trader
News
Be automatically updated! Get company news by RSS.
Click here for the feed: RSS Feed or learn more about the benefits RSS
| Date/Time | Headline | Source |
|---|---|---|
| 1 | ||
| 04-11-09 | PRN |
|
|
Avacta Group plc
Avacta Group plc, the company providing innovative, high value technologies and services to the pharmaceutical and diagnostics markets, will announce its results for the year ended 31 July 2009, on Thursday 26 November. An analyst presentation will take place at the offices of Daniel Stewart & Company Plc, Becket House, 36 Old Jewry, London EC2R 8DD, on the day and those wishing to attend should contact Kathy Boate at the details below.
Enquiries:
Alastair Smith, Chief Executive Officer www.avacta.com
Daniel Stewart & Company Plc
Simon Leathers
Henry Turcan Notes to Editors: About Avacta Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address unmet needs in the biopharmaceutical and healthcare sectors. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High end analytical instruments and leading edge contract research services are being provided to the biopharmaceutical and healthcare/personal-care materials sectors through the Group's biotech support division, Avacta Analytical. High value solutions for rapid, point of care diagnostics based on these core bio-analytical technologies, with a near term focus on veterinary diagnostics, are being delivered through Avacta Animal Health. Longer term these technologies will be transferred into the human clinical diagnostics market. Avacta listed on AIM in August 2006.
END More |
||
| 21-10-09 | AFX UK Focus |
|
|
LONDON, Oct 21 (Reuters) - Avacta Group Plc:
products ((London Equities Newsroom; +44 20 7542 7717)) (For more news, please click here)
COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. More |
||
| 21-10-09 | PRN |
|
|
Avacta Group plc
Target of becoming a substantial and profitable business supporting the life
Avacta Group plc ("Avacta" or "the Company"), the biophysics company which provides innovative high value technologies and services to the pharmaceutical and diagnostics markets, announces that it proposes to raise up to £2 million (gross of expenses) from a conditional placing of 133,333,328 new ordinary shares of 0.1 pence each ("New Ordinary Shares") at a price of 1.5 pence per Ordinary Share (the "Placing"). 96,666,662 of the New Ordinary Shares have been placed by Daniel Stewart & Co plc ("Daniel Stewart") with institutional and other existing and new shareholders pursuant to a Placing agreement, the details of which are set out below. The remaining 36,666,666 New Ordinary Shares are to be placed by Daniel Stewart using a reasonable endeavours basis within 6 weeks of this announcement and this will be the subject of a separate announcement. Use of Proceeds & Strategy The cash proceeds of the Placing, amounting to approximately £2 million (before expenses) will be used to accelerate Avacta from the strong position it has achieved since admission to AIM, towards its near term goal of being a profitable and substantial business providing products and services to support the life sciences sector. The funds will be deployed to support the rapid growth of Avacta's own products and services and to support further acquisition opportunities. Since coming to AIM in late 2006 Avacta has exceeded its stated developmental and commercial milestones and has established two operating businesses in its target markets of drug development and diagnostics. These businesses form the routes to market for its high value technology products. The Company recently announced the first sales of Optim, its flagship product, which is designed to significantly reduce risk and cost throughout the biopharmaceutical drug development process. In addition, the Company is expected to launch its first diagnostic product, Midas, into the veterinary healthcare market in early 2010. This system will be capable of delivering a wide menu of rapid diagnostic blood tests for both veterinary and, in due course, human healthcare. Avacta has several other products in development which will follow Optim into the drug development market and has already received sufficient customer interest indicating considerable demand. The funds raised will be used to accelerate the commercialisation of these new products and diagnostic tests through improvements in infrastructure and enhanced commercial teams. In addition to its organic product pipeline, the Company is pleased to report its achievements in integrating the four complementary acquisitions made during the past two years. The Company has identified and is exploring other potential acquisition targets each of which could bring technologies and expertise into the growing business. The Placing The Placing Agreement contains warranties in favour of Daniel Stewart given by the Company and the Directors with respect to its business and certain matters connected with the Placing. In addition, the Company has given customary indemnities to Daniel Stewart in connection with the Placing and their performance of services in relation to the Placing. Daniel Stewart has certain rights to terminate the Placing Agreement in specified circumstances. Pursuant to the Placing, certain Directors of the Company will subscribe for up to 3,333,331 new Ordinary Shares in aggregate. Details of the Directors' subscriptions and resultant holdings are listed in the table below:
Pursuant to the Placing, IP Group plc and IP Venture Fund, a fund managed by IP Group in which IP Group is an investor (together "IP Group") will subscribe for up to 36,666,666 New Ordinary Shares at the Placing Price. Following Admission, IP Group will be interested in 283,168,762 ordinary shares, representing 22.7 per cent of the Company's issued share capital on Admission. As IP Group is a significant shareholder in the Company, the subscription for New Ordinary Shares by IP Group is a Related Party Transaction as defined by the AIM Rules. Accordingly, the Directors have consulted with Daniel Stewart and together they consider that the terms of the subscription by IP Group are fair and reasonable insofar as the shareholders are concerned. Admission Application has been made for the New Ordinary Shares to be admitted to trading on the AIM market of London Stock Exchange plc and dealings are expected to commence on 22 October 2009. The New Ordinary Shares will rank pari passu with existing shares in issue. Following the Placing, Avacta's issued share capital comprises 1,249,168,733 ordinary shares of par value 0.1 pence each.
For further information, please contact:
Tim Sykes, Finance Director
Simon Leathers/Stewart Dickson
Haggie Financial LLP
Notes to Editors: About Avacta Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address unmet needs in the biopharmaceutical and healthcare sectors. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High end analytical instruments and leading edge contract research services are being provided to the biopharmaceutical and healthcare/personal-care materials sectors through Avacta's biotech support division, Avacta Analytical. High value solutions for rapid, point of care diagnostics based on these core bio-analytical technologies, with a near term focus on veterinary diagnostics, are being delivered through Avacta Animal Health. Longer term these technologies will be transferred into the human clinical diagnostics market. Avacta listed on AIM in August 2006.
END More |
||
| 06-10-09 | RNS |
|
|
RNS Number : 2727A Avacta Group PLC 06 October 2009 Avacta Group plc Momentum builds for flagship technology - Optim: huge annual revenues opportunity Reducing risk and costs for biopharmaceutical developers Avacta Group plc ("Avacta" or the "Company"), which provides innovative, high value technologies and services to the pharmaceutical and diagnostics markets, is pleased to announce that, following the very recent announcement of its first order from a global biopharmaceutical developer for its recently launched flagship product, Optim, a second order from a similar global biopharmaceutical company has been received. This is significant news in that it demonstrates the start of sales momentum and Optim's powerful value proposition. Moreover, it indicates the effectiveness of Avacta's marketing team which bodes well for the anticipated near term launch of MIDAS, a high value, high end bench top instrument for the veterinary and human diagnostics sectors. Costing up to £100k and with a large addressable market encompassing the biopharmaceutical sector, parts of the chemical and food industries and the academic life sciences research sector, the revenues from Optim and future hardware upgrades are potentially huge. Moreover, each unit should deliver an attractive recurring revenue stream from consumable sales, annual servicing, software updates and support packages. About Optim: Optim fills a significant gap in the market providing detailed analysis using only very small sample volumes. For the first time this enables drug developers to gain vital information about product performance in the early stages of product development, when very limited quantities of material are available, helping to reduce the risk of later stage failure. An Optim system can cost up to £100k. However, since Optim uses minute amounts of sample and is fully automated, it can deliver results in a fraction of the time and at a fraction of the cost of other methods and can therefore yield a return on investment for customers in only a few months. Alastair Smith, Chief Executive, Avacta Group, commented: "I am extremely pleased to announce our second order for Optim, received very shortly following the first which was announced last week. This is a clear manifestation of the strong sales pipeline that I reported on and further supports our confidence in future sales levels." "Optim has been received by potential customers enthusiastically as a unique tool that will allow them to characterize their drug compounds at an early stage of development and provide information that will help reduce the risk of product development and ultimately reduce the cost to patients of these new drugs. The value proposition to the end user is very compelling." 6 October 2009 Enquiries:
Alastair Smith, Chief Executive Officer www.avacta.com
Notes to Editors: About Avacta Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address unmet needs in the biopharmaceutical and healthcare sectors. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High end analytical instruments and leading edge contract research services are being provided to the biopharmaceutical and healthcare/personal-care materials sectors through the Group's biotech support division, Avacta Analytical. High value solutions for rapid, point of care diagnostics based on these core bio-analytical technologies, with a near term focus on veterinary diagnostics, are being delivered through Avacta Animal Health. In the longer term these technologies will be transferred into the human clinical diagnostics market. Avacta listed on AIM in August 2006. This information is provided by RNS The company news service from the London Stock Exchange END
NRABLBDGLUGGGCU More |
||
| 28-09-09 | PRN |
|
|
Avacta Group plc
Avacta Group plc ("Avacta" or the "Company"), the company providing innovative, high value technologies and services to the pharmaceutical and diagnostics markets, is pleased to announce the first order from a global biopharmaceutical developer for its recently launched flagship product Optim, an analytical technology that is designed to reduce risk in biopharmaceutical development and help drug companies bring optimised products to market quicker and at lower cost. The Directors believe that this is a significant and pivotal step for the Company as it provides validation for its flagship product and a clear demonstration of market demand. Optim fills a significant gap in the market providing detailed analysis using only very small sample volumes. For the first time this enables drug developers to gain vital information about product performance in the early stages of product development, when very limited quantities of material are available, helping to reduce the risk of later stage failure. An Optim system can cost up to £100k. However, since Optim uses minute amounts of sample and is fully automated, it can deliver results in a fraction of the time and at a fraction of the cost of other methods and can therefore yield a return on investment for customers in only a few months. Additionally Optim has several hardware/software add-ons and consumables currently being developed in response to other clearly identified market needs. These add-ons will, when integrated with Optim, build up a comprehensive and unique biophysical analysis system for biopharmaceutical drug developers. The Company is committed to bring these additional products to market as quickly as possible. Alastair Smith, Chief Executive, Avacta Group, commented: "Optim is designed to revolutionise the way in which biological drugs are developed. It will make a major contribution to optimizing product performance and reducing the risk and cost of drug development, particularly when applied in the early stages of the drug development process when it could identify problems that cause expensive later stage product failure. Optim will help drug developers bring better products to market quicker and more cheaply, which should result in a reduction in the cost of these new drugs to patients. "I am delighted to announce to the market that we have converted the first order from a strong pipeline and that the very positive response we have received from our discussions with potential customers gives us confidence in future sales levels. "We will continue to work hard towards building a strong, profitable Group focused on providing high value products and services to support businesses in the Life Sciences sector through commercialization of our own technology and potentially through further acquisitions."
Enquiries:
Officer
Daniel Stewart & Company Plc
Simon Leathers
Henry Turcan Notes to Editors: About Avacta Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address unmet needs in the biopharmaceutical and healthcare sectors. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High end analytical instruments and leading edge contract research services are being provided to the biopharmaceutical and healthcare/personal-care materials sectors through the Group's biotech support division, Avacta Analytical. High value solutions for rapid, point of care diagnostics based on these core bio-analytical technologies, with a near term focus on veterinary diagnostics, are being delivered through Avacta Animal Health. Longer term these technologies will be transferred into the human clinical diagnostics market. Avacta listed on AIM in August 2006.
END More |
||
| 16-09-09 | RNS |
|
|
RNS Number : 1789Z Avacta Group PLC 16 September 2009
of existing shares to which voting rights are
attached:
boxes)
An acquisition or disposal of financial instruments which may result in
the acquisition of shares already issued to which voting rights are
attached
An event changing the breakdown of voting rights
Other (please specify):
notification obligation:
4. Full name of shareholder(s) (if different from
3.):
threshold is crossed or reached if different):
8. Notified details:
A: Voting rights attached to shares
CODE
ISIN GB0033519546
B: Financial Instruments
Resulting situation after the triggering transaction xii
Total (A+B)
Number of voting rights % of voting rights
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable xv: Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:
This information is provided by RNS The company news service from the London Stock Exchange END
HOLGGGMLDVZGLZM More |
||
| 11-09-09 | RNS |
|
|
RNS Number : 9568Y
Avacta Group PLC
11 September 2009
of existing shares to which voting rights are
attached:
boxes)
An acquisition or disposal of financial instruments which may result in
the acquisition of shares already issued to which voting rights are
attached
An event changing the breakdown of voting rights
Other (please specify):
notification obligation:
4. Full name of shareholder(s) (if different from
3.):
threshold is crossed or reached if different):
8. Notified details:
A: Voting rights attached to shares
CODE
ISIN GB0033519546
B: Financial Instruments
Resulting situation after the triggering transaction xii
Total (A+B)
Number of voting rights % of voting rights
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable xv: Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: This information is provided by RNS The company news service from the London Stock Exchange END
HOLZGGMLKMKGLZM More |
||
| 11-09-09 | RNS |
|
|
RNS Number : 9535Y Avacta Group PLC 11 September 2009 Avacta Group plc ("Avacta" or "the Company") Holdings in Company TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Avacta Group plc 2. Reason for the notification: An acquisition or disposal of voting rights 3. Full name of person(s) subject to the notification obligation: Mr Robert Quested 4. Full name of shareholder(s) (if different from 3.): 5. Date of the transaction (and date on which the threshold is crossed or reached if different): 11/9/09 6. Date on which issuer notified: 11/09/09
7. Threshold(s) that is/are crossed or reached:
8. Notified details:
A: Voting rights attached to shares
possible using the ISIN CODE
Resulting situation after the triggering transaction
possible using the ISIN CODE
GB0033519546 0 0 0 B: Qualifying Financial Instruments Resulting situation after the triggering transaction
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Total (A+B+C) Number of voting rights % of voting rights
0 0 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): Proxy Voting: 10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:
15. Contact telephone number: 0097 1507 891007 This information is provided by RNS The company news service from the London Stock Exchange END
HOLKGGMLDMNGLZM More |
||